According to the Zhitong Finance App, Laimei Pharmaceutical (30006.SZ) disclosed its 2022 annual performance forecast. The company expects a net loss of 55 million yuan to 75 million yuan to shareholders of listed companies in 2022, and a net loss of 100 million yuan to 120 million yuan after deducting non-recurring profit and loss.

The announcement showed that due to the influence of the collection policy, sales volume and prices of the company's esomeprazole enteric capsules and other varieties declined further; during the reporting period, due to the epidemic, the number of hospitalized patients not related to COVID-19 decreased, which also had a certain impact on the delivery and sales of the company's related products. Overall, sales revenue fell by about 300 million yuan over the reporting period, and profits declined accordingly.